Long-Term Study Confirms Sustained Efficacy and Safety of Zigakibart in IgA Nephropathy Patients
In a significant advancement for the treatment of IgA nephropathy (IgAN), recent findings from a 100-week Phase 1/2 clinical trial ...
In a significant advancement for the treatment of IgA nephropathy (IgAN), recent findings from a 100-week Phase 1/2 clinical trial ...
Sotagliflozin, an innovative drug approved by the Food and Drug Administration, represents a significant advancement in the treatment of type ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine